MARKET

ARNA

ARNA

Arena Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

60.08
-1.00
-1.64%
After Hours: 60.08 0 0.00% 16:23 09/24 EDT
OPEN
60.72
PREV CLOSE
61.08
HIGH
61.31
LOW
59.55
VOLUME
393.87K
TURNOVER
--
52 WEEK HIGH
90.19
52 WEEK LOW
45.50
MARKET CAP
3.67B
P/E (TTM)
-7.3554
1D
5D
1M
3M
1Y
5Y
JPMorgan Small Cap Sustainable Leaders Fund Buys Arena Pharmaceuticals Inc, Unifi Inc, ...
GuruFocus News · 2d ago
Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that the Compensation Committee of its Board of Directors granted to 20 new employees inducement stock options to purchase an aggregate of 33,340 shares of its common stock and 15,655 inducement re...
Business Wire · 09/17 20:05
AzurRx (AZRX) Announces First Wave Bio Acquisition for $229M
Zacks.com · 09/14 15:35
7 Busted Biotech Stocks Due for a Rebound
Investor Place · 09/08 16:25
Hancock Horizon Burkenroad Small Cap Fund Buys Earthstone Energy Inc, Waitr Holdings Inc, OPKO ...
GuruFocus News · 09/04 06:38
Arena Pharmaceuticals to Host Virtual R&D Investor Calls and Participate in Upcoming September Investor Conferences
PARK CITY, Utah, September 02, 2021--Arena to host two virtual R&D Investor calls for analysts and investors focused on etrasimod programs in gastroenterology and dermatology.
Business Wire · 09/02 12:30
MariMed, Hexo & Aurora Cannabis Among Top Cannabis Movers For September 1, 2021
GAINERS: cbdMd, Inc. (AMEX:YCBD) shares closed up 9.3% at $2.35 with an estimated market cap of $135.8M.
Benzinga · 09/01 22:20
DAFNA Capital Management LLC Buys Theravance Biopharma Inc, Nurix Therapeutics Inc, F-star ...
GuruFocus News · 08/24 16:38
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ARNA. Analyze the recent business situations of Arena Pharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 16 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ARNA stock price target is 95.25 with a high estimate of 120.00 and a low estimate of 76.00.
EPS
Institutional Holdings
Institutions: 357
Institutional Holdings: 60.23M
% Owned: 98.62%
Shares Outstanding: 61.07M
TypeInstitutionsShares
Increased
80
4.09M
New
39
1.25M
Decreased
70
2.51M
Sold Out
34
2.09M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.13%
Pharmaceuticals & Medical Research
-1.02%
Key Executives
Non-Executive Chairman/Independent Director
Garry Neil
President/Chief Executive Officer/Director
Amit Munshi
Chief Financial Officer/Executive Vice President
Laurie Stelzer
Executive Vice President/General Counsel/Secretary
Joan Schmidt
Executive Vice President
Vincent Aurentz
Executive Vice President
Robert Lisicki
Senior Vice President
Paul Streck
Director
Tina Nova
Director
Steven Schoch
Independent Director
Jayson Dallas
Independent Director
Oliver Fetzer
Independent Director
Kieran Gallahue
Independent Director
Jennifer Jarrett
Independent Director
Katharine Knobil
Independent Director
Nawal Ouzren
No Data
  • All
  • Financials
  • Insiders
More
About ARNA
Arena Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing small molecule drugs across a range of therapeutic areas. The Company has three primary investigational clinical programs: etrasimod (APD334) in Phase II evaluation for ulcerative colitis, APD371 entering Phase II evaluation for the treatment of pain associated with Crohn's disease, and ralinepag (APD811) in Phase II evaluation for pulmonary arterial hypertension (PAH). The Company's drug, Lorcaserin, is approved for marketing in the United States and South Korea for the indication of weight management. The Company's drug candidates in clinical development include APD334 for autoimmune diseases, ralinepag for vascular diseases and APD371 for pain. The Company's programs under collaboration include nelotanserin for dementia-associated psychosis, temanogrel for thrombotic diseases, and an undisclosed orphan GPCR for central nervous system (CNS) indication(s).

Webull offers kinds of Arena Pharmaceuticals, Inc. stock information, including NASDAQ:ARNA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ARNA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ARNA stock methods without spending real money on the virtual paper trading platform.